Tackling Gram-negative Resistance During the Pandemic Era
Going Above and Beyond Through Collaborative Care

Join us for a CPE Webinar!
Wednesday, October 27, 2021 • 12:00 - 1:00 PM MT

Educational Need

Infections caused by multidrug-resistant (MDR) Gram-negative bacteria continue to challenge clinicians and are responsible for substantial morbidity and mortality. Timely administration of appropriate antimicrobial therapy is a major predictor of clinical outcomes. The COVID-19 pandemic has further exacerbated the challenges of these serious bacterial infections in hospitals. As clinicians gain knowledge and adjust practice behavior during these times, they can again focus on optimal utilization of antimicrobials individualized for each patient scenario. Clinical pharmacists must play a lead role in these antimicrobial stewardship efforts by providing guidance on antibiograms, proper escalation/de-escalation of therapy, and pathogen-specific approaches to management.

Learning Objectives

At the conclusion of the educational activity, the learner should be able to:

- Explain the impact of local epidemiological trends and resistance mechanisms of Gram-negative bacteria on initial antimicrobial selection
- Evaluate the potential role of newer and novel antimicrobial agents in targeting antimicrobial-resistant Gram-negative pathogens
- Apply antimicrobial stewardship strategies to improve appropriate use of antimicrobials
- Utilize a collaborative care model to improve patient outcomes during the pandemic era

Target Audience

This continuing pharmacy education activity meets the needs of pharmacists in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, and academia. This program targets pharmacists who are at the forefront of caring for adult patients with serious bacterial infections.

Educational Format

This program is designed to address key unmet needs when managing serious Gram-negative bacterial infections, such as timely diagnosis, appropriate initial treatment selection, and assessing outcomes. Topics discussed include:

- Gram-negative resistance mechanisms
- Impact of local epidemiology
- Clinical data of newer antimicrobials targeting MDR Gram-negative bacteria
- Patient stratification to guide treatment selection
- Pathogen-specific approaches when managing nosocomial pneumonia

There is no fee to attend this CPE activity.

Faculty

James S. Lewis II, PharmD, FIDSA
ID Clinical Pharmacy Coordinator
& Adjunct Associate Professor
Oregon Health and Science University
Departments of Pharmacy & Infectious Diseases
Portland, OR

Disclosure of Financial Relationships with Ineligible Companies

Center for Independent Healthcare Education and Vemco MedEd fully comply with the Standards for Integrity and Independence in Accredited Continuing Education in development of CME/CPE activities. We require the full disclosure of financial relationships with ineligible companies from all individuals in a position to influence the content of a certified activity, in any amount occurring within the past 24 months. All relevant financial relationship is identified by the provider and mitigated to prevent inserting commercial bias into content. All identified relevant financial relationships are disclosed to the learners prior to the activity. The faculty is further required to disclose discussion of off-label uses in their presentations.